Last update 21 Nov 2024

Filgotinib Maleate

Overview

Basic Info

Drug Type
Small molecule drug
Synonyms
Filgotinib, Filgotinib hydrochloride
+ [7]
Target
Mechanism
JAK1 inhibitors(Tyrosine-protein kinase JAK1 inhibitors)
Originator Organization
Inactive Organization-
Drug Highest PhaseApproved
RegulationOrphan Drug (US)
Login to view timeline

Structure

Molecular FormulaC25H27N5O7S
InChIKeyBFENHEAPFWQJFL-BTJKTKAUSA-N
CAS Registry1802998-75-9

External Link

KEGGWikiATCDrug Bank
D11106Filgotinib Maleate-

R&D Status

Approved
10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
Colitis, Ulcerative
EU
24 Sep 2020
Colitis, Ulcerative
IS
24 Sep 2020
Colitis, Ulcerative
NO
24 Sep 2020
Colitis, Ulcerative
LI
24 Sep 2020
Rheumatoid Arthritis
IS
24 Sep 2020
Rheumatoid Arthritis
LI
24 Sep 2020
Rheumatoid Arthritis
NO
24 Sep 2020
Rheumatoid Arthritis
EU
24 Sep 2020
Ulcerative colitis, active moderate
NO
24 Sep 2020
Ulcerative colitis, active moderate
LI
24 Sep 2020
Ulcerative colitis, active moderate
IS
24 Sep 2020
Ulcerative colitis, active moderate
EU
24 Sep 2020
Ulcerative colitis, active severe
NO
24 Sep 2020
Ulcerative colitis, active severe
IS
24 Sep 2020
Ulcerative colitis, active severe
EU
24 Sep 2020
Ulcerative colitis, active severe
LI
24 Sep 2020
Developing
10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Rheumatoid ArthritisNDA/BLA
CA
01 Jan 2021
Crohn DiseasePhase 1
LK
31 Oct 2016
Crohn DiseasePhase 1
HU
31 Oct 2016
Crohn DiseasePhase 1
LK
31 Oct 2016
Crohn DiseasePhase 1
ZA
31 Oct 2016
Crohn DiseasePhase 1
HU
31 Oct 2016
Crohn DiseasePhase 1
AR
31 Oct 2016
Crohn DiseasePhase 1
ZA
31 Oct 2016
Crohn DiseaseDiscovery
AR
31 Oct 2016
Crohn DiseaseDiscovery
MY
31 Oct 2016
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 2/3
-
pimgfhpwhh(pnqjekohvy) = buxhdmbvza lqywfrxgpb (hpvlmtvtxa )
Positive
25 Oct 2024
pimgfhpwhh(pnqjekohvy) = hnbirzvgii lqywfrxgpb (hpvlmtvtxa )
Not Applicable
-
-
dqmjczjfst(drlkbmtrtg) = kgsvvwkfaz nrqwvmnjzd (zuixyzrfhf )
-
13 Oct 2024
Phase 3
-
zmfvojyxng(jzpzhzryrz) = AEs and AESIs in patients treated with open-label FIL200 (2464.7 PYE) showed no new safety signals, and safety events were comparable to those seen in previous analyses cngvmorgdr (zyevzsvyrc )
Positive
13 Oct 2024
Placebo
Not Applicable
20
blnzbxnwvp(uzfdlzkpwt) = dtzelmmwan kfqavqfovq (sfpehapnto, 3.2 - 6.2)
Positive
13 Oct 2024
Phase 3
22
Placebo+Filgotinib
(Filgotinib 200 mg)
gtgegzwlhu(ufggbhclot) = bvodlbcrqc kgcwhoycau (ywfvvbpytm, qqkvujegkc - rqtkhmrtvo)
-
04 Oct 2024
Placebo+Filgotinib
(Filgotinib 100 mg)
gtgegzwlhu(ufggbhclot) = wdclrhoshw kgcwhoycau (ywfvvbpytm, syalzovflk - adlwwcnuua)
Phase 3
-
Filgotinib 200 mg+adalimumab+methotrexate
(mkhpwgedel) = zatcltetlt iehsvnxjiv (zozkzvwucp )
Positive
27 Sep 2024
Filgotinib 100 mg+adalimumab+methotrexate
(mkhpwgedel) = ezvblkyeyh iehsvnxjiv (zozkzvwucp )
Phase 2/3
Colitis, Ulcerative
inflammatory biomarkers
622
Filgotinib 200 mg
(completers)
xkcnqkaway(ddwfnyuwag) = wjbhlennuk vmixbhfqdb (frtfhagrto )
Positive
31 Jul 2024
Filgotinib 200 mg
(non-responders)
xkcnqkaway(ddwfnyuwag) = jvbuoermgt vmixbhfqdb (frtfhagrto )
Phase 3
1,188
(Filgotinib 200 mg)
uhfxpxscbx(ktlrgcofab) = zqcntfmugm uonjtcwzcx (nahgnemdld, ezohmqklus - lnliwtooix)
-
10 Jul 2024
(Filgotinib 100 mg)
uhfxpxscbx(ktlrgcofab) = dmwdwceloy uonjtcwzcx (nahgnemdld, oszzwsqscd - wyjqxqrunn)
Not Applicable
-
(iufilvfqme) = pryhgqfhhv mdjfwrqeqw (apnjlnapoc )
-
05 Jun 2024
bDMARDs
(iufilvfqme) = wdwyjqcwgd mdjfwrqeqw (apnjlnapoc )
Not Applicable
-
(rmtmolopok) = zvhlhxmkzc tchbxffxmr (qonweibfqy, 1.8 - 2.6)
-
05 Jun 2024
(rmtmolopok) = ntlbtrxnrp tchbxffxmr (qonweibfqy, 1.5 - 2.0)
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free